The invention discloses a PH
response type modified polydopamine nano preparation loaded with
icariin and application of the PH
response type modified polydopamine nano preparation in
myocardial ischemia resistance, and belongs to the technical field of biological
medicine. The nano preparation takes polydopamine (PDA) as a carrier core, the carrier core is modified by methoxy
polyethylene glycol (mPEG) and then loaded with
icariin (ICA), and the nano preparation is named as mPEG-PDA (at) ICANPs; the preparation process comprises the steps of synthesis of mPEG-OTs, synthesis of mPEG-EDA, synthesis of PDA, preparation of mPEG-PDANPs and preparation of mPEG-PDA (at) ICANPs, under the optimal condition, the particle size of the preparation is 179.6 + / -0.432 nm, PDI is 0.130 + / -0.004, the
Zeta potential is 23.4 + / -0.436 mV, the stability is good after the preparation is stored in a dark place at 4 DEG C for 30 days, the ICA
drug loading capacity is 14.6 + / -1.08%, the encapsulation efficiency is 64.37 + / -2.31%, and the
drug cumulative release rate reaches 73.31 + / -1.64% (pH response
drug release) in an environment with the pH value of 6.5 for 72 hours. An in-vitro H9c2
cell OGD model experiment proves that the preparation can remarkably improve the
survival rate of ischemic myocardial cells, inhibit
apoptosis and reduce LDH release, and the effect of the preparation is superior to that of free ICA. The invention provides an efficient targeting
drug delivery system for resisting
myocardial ischemia, and has important clinical application value.